These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 30970612)

  • 21. Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System.
    Majláth Z; Toldi J; Fülöp F; Vécsei L
    Curr Med Chem; 2016; 23(9):874-83. PubMed ID: 26872942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nitric oxide, a new player in L-DOPA-induced dyskinesia?
    Del-Bel E; Padovan-Neto FE; Bortolanza M; Tumas V; Aguiar AS; Raisman-Vozari R; Prediger RD
    Front Biosci (Elite Ed); 2015 Jan; 7(1):168-92. PubMed ID: 25553372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
    Rascol O; Arnulf I; Peyro-Saint Paul H; Brefel-Courbon C; Vidailhet M; Thalamas C; Bonnet AM; Descombes S; Bejjani B; Fabre N; Montastruc JL; Agid Y
    Mov Disord; 2001 Jul; 16(4):708-13. PubMed ID: 11481696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa-related wearing-off in Parkinson's disease: identification and management.
    Pahwa R; Lyons KE
    Curr Med Res Opin; 2009 Apr; 25(4):841-9. PubMed ID: 19228103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
    Sebastianutto I; Cenci MA
    Curr Opin Pharmacol; 2018 Feb; 38():81-89. PubMed ID: 29625424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
    Thomsen BL; Herz DM; Siebner HR; Løkkegaard A
    Ugeskr Laeger; 2017 Mar; 179(10):. PubMed ID: 28263159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
    Simon N; Viallet F; Boulamery A; Eusebio A; Gayraud D; Azulay JP
    Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease.
    Karamanakos PN; Pappas P; Marselos M
    Pharm World Sci; 2008 Jan; 30(1):1-2. PubMed ID: 17597418
    [No Abstract]   [Full Text] [Related]  

  • 33. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.
    Cristina S; Zangaglia R; Mancini F; Martignoni E; Nappi G; Pacchetti C
    Clin Neuropharmacol; 2003; 26(3):146-50. PubMed ID: 12782917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Nicholson SL; Brotchie JM
    Eur J Neurol; 2002 Nov; 9 Suppl 3():1-6. PubMed ID: 12464115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential nondopaminergic drugs for Parkinson's disease.
    Silverdale MA; Fox SH; Crossman AR; Brotchie JM
    Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.